Apexigen Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Apexigen inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Apexigen Inc Today - Breaking & Trending Today

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s. ....

United States , Laras Sullivan , Pamela Connealy , Apexigen Inc , Company Annual Report On Form , Pyxis Oncology Inc , Exchange Commission , Antibody Drug Conjugate , Pyxis Oncology , Private Securities Litigation Reform Act , Annual Report ,

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

PYX-201 Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024. PYX-106 : Phase 1 trial now focusing on NSCLC and other tumor types; data expected 2H 2024. Cash runway. ....

United States , Pam Connealy , Laras Sullivan , Apexigen Inc , Company Quarterly Report On Form , Pyxis Oncology Inc , Chief Executive Officer , Pyxis Oncology , Private Securities Litigation Reform Act , Quarterly Report , Consolidated Statements ,

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Pam Connealy , Laras Sullivan , Apexigen Inc , Pyxis Oncology Inc , Company Quarterly Report On Form , Oncology Announces Initiatives , Prioritize Lead , Reports Financial Results , Provides Corporate , Chief Executive Officer , Pyxis Oncology , Private Securities Litigation Reform Act , Quarterly Report , Consolidated Statements ,

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

07.11.2023 - PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024. PYX-106 (a fully human immunotherapy . ....

United States , Pam Connealy , Laras Sullivan , Company Quarterly Report On Form , Apexigen Inc , Pyxis Oncology Inc , Chief Executive Officer , Pyxis Oncology , Private Securities Litigation Reform Act , Quarterly Report , Consolidated Statements ,

Invivyd Appoints William Duke as Chief Financial Officer

WALTHAM, Mass., Sept. 05, 2023 Invivyd, Inc. , a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the. ....

Scott Young , William Duke , Dave Hering , Gabriella Linville Engler , Business Administration , Pyxis Oncology Inc , Bentley College , Valeritas Inc , Pulmatrix Inc , Apexigen Inc , Invivyd Inc , Stonehill College , Kaleido Biosciences Inc , Genzyme Corporation , Exchange Commission , Chief Financial , Chief Executive Officer , Chief Financial Officer , Pyxis Oncology , Before Apexigen , Kaleido Biosciences , Private Securities Litigation Reform Act , Annual Report ,